SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

HEMGENIX

QURE·uniQure N.V.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA approval November 22, 2022); pivotal Phase 3 HOPE-B trial completed primary analysis, long-term follow-up
Time to market
Approved and on the market since November 2022 (U.S.), commercialized worldwide by CSL Behring, but currently constrained by a temporary global stockout announced March 2026
Why 3/10
HEMGENIX is already approved (FDA, Nov 22, 2022) with no pending PDUFA/readout for this molecule in the next ~12 months, the defining binary passed, so the score caps at 3-5; it is set at 3 because the drug is now a minor, largely-monetized royalty/manufacturing revenue line for QURE, whose market value (~$2.3B) and near-term catalysts are driven by the separate AMT-130 program, and the only live HEMGENIX event (resolution of CSL's global stockout) is event-driven, not a scheduled decision.
Actionable Insight NEUTRAL

For QURE holders, stop thinking of HEMGENIX as the thesis: the stock now trades on AMT-130 (Huntington's), BLA submission on track for Q3 2026 and topline 4-year data expected September 2026. Watch HEMGENIX only as a modest cash-flow line: CSL has been in a manufacturing-related temporary global stockout since March 2026 and, as of its July 24, 2026 update, supply was still being actively managed, any resumption announcement or CSL sales disclosure is a minor, non-binary event for QURE (which already sold $375M of its royalty tier to HealthCare Royalty/Sagard).

Price Chart

Loading chart...

Executive Summary

HEMGENIX (etranacogene dezaparvovec-drlb), developed by uniQure (Nasdaq: QURE) and commercialized by CSL Behring, is the first FDA-approved gene therapy for hemophilia B (approved Nov 22, 2022) with durable efficacy shown in the pivotal HOPE-B trial. uniQure's economics are modest and partly monetized: it received a $450M upfront from CSL in 2020 plus milestones, then sold its lowest royalty tier for $375M upfront; HEMGENIX-related income is a small part of QURE's ~$16M 2025 total revenue, and the company's value now hinges on its separate Huntington's program (AMT-130). The live commercial overhang is CSL's manufacturing-related temporary global stockout, announced March 17, 2026, with a follow-up July 24, 2026 update confirming supply was still being managed, a real drag on the product's ramp but not a swing factor for QURE stock.

How It Works

A one-time intravenous gene therapy. It uses a harmless, engineered virus (AAV5) to deliver a working copy of the F9 gene into liver cells, so the patient's own liver produces clotting factor IX, aiming to reduce or eliminate the need for lifelong, regular factor IX replacement infusions in adults with hemophilia B.

Trial Status

Approval rests on the HOPE-B Phase 3 trial (largest gene therapy trial in hemophilia B), which showed mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion; CSL reported 3-year durability, safety and bleed-protection data in December 2023, and later follow-up out to three years post-dose has been presented. The product is now in commercial phase with a global supply interruption under active management.

The Two-Sided Case

▲ Bull Case4
First-ever FDA-approved gene therapy for hemophilia B (Nov 22, 2022), a one-time infusion with durable benefit versus lifelong prophylaxis, supported by HOPE-B data: mean factor IX activity of 39% at six months and 36.7% at 24 months, with 3-year durability data reported by CSL in December 2023.
Commercialized by a large partner (CSL Behring), which licensed global rights in June 2020 for $450M upfront plus up to $1.6B in milestones, uniQure got paid early and de-risked development.
uniQure monetized its lowest royalty tier on HEMGENIX net sales for a $375M upfront (deal worth up to ~$400M, capped at 1.85x purchase price through June 30, 2032 or 2.25x through Dec 31, 2038), extending cash runway without new dilution at the time.
FiercePharma's coverage of the stockout described HEMGENIX as 'the last available hemophilia gene therapy,' underscoring that it faces little-to-no direct marketed competition in its class.
▼ Bear Case5
CSL declared a temporary GLOBAL stockout of HEMGENIX on March 17, 2026 (manufacturing-related per FiercePharma), delaying treatment for patients in countries with commercial access; the July 24, 2026 CSL update shows supply was still being actively managed, a commercial overhang with no dated resolution.
HEMGENIX is no longer a meaningful value driver for QURE: total company revenue was only $16.1M in 2025 and $5.8M in Q2 2026, while the market cap (~$2.3B per local analysis) and analyst attention are centered on AMT-130 (Huntington's), HEMGENIX-specific news moves QURE little.
uniQure already sold its lowest royalty tier ($375M upfront to HealthCare Royalty/Sagard), so a large share of the drug's future upside no longer accrues to QURE shareholders.
High-priced one-time gene therapies face slow uptake, and a supply interruption can permanently forfeit patient starts; additionally QURE diluted holders ~10% with a $259M follow-on in June 2026 (funding AMT-130, not HEMGENIX).
Data risk remains on durability: factor IX levels declined modestly between 6 and 24 months in HOPE-B (39% to 36.7% mean activity), and long-term durability beyond three years is still being generated.

Upcoming Catalysts

  • Resolution/restoration of HEMGENIX supply, CSL has issued community updates (March 17, 2026 stockout; July 24, 2026 status) and further announcements on availability are the only scheduled-type events specific to this drug
  • CSL quarterly/annual net sales disclosures for HEMGENIX and any resulting change in uniQure's royalty/manufacturing revenue line
  • Company-level (different drug, but the real QURE drivers): AMT-130 BLA submission on track Q3 2026 and topline four-year AMT-130 data expected September 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

uniQure N.V. 8-K QURE ·Originating report

Sources · 19

Hover a chip for the title
1 uniqure.com2 hemgenix.com3 hemophilianewstoday.com4 newsroom.csl.com5 bleeding.org6 fda.gov7 drugs.com8 nejm.org9 newsroom.csl.com10 newsroom.csl.com11 hemophiliafed.org12 hemob.org13 bleeding.org14 fiercepharma.com15 pharmaceutical-technology.com16 hcrx.com17 biospace.com18 globenewswire.com19 sec.gov